Author

Mai Komori

Observed names: Komori, Mai, MAI FUKUSHIMA KOMORI

Institution: VLP Therapeutics (United States)

Observed institutions: Okayama University, VLP Therapeutics (United States)

ORCID: 0000-0001-8999-3456

Observed ORCID: 0000-0001-8999-3456

OpenAlex ID: A5010836657

Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study

2023 · Wataru Akahata, Takashi Sekida, et al. · Cell Reports Medicine · 46

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern

2023 · Mai Komori, Takuto Nogimori, et al. · Nature Communications · 39

Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine

2024 · Masayuki Aboshi, Kenta Matsuda, et al. · iScience · 37

Incorporation of 5-methylcytidine alleviates RIG-I–mediated innate immune responses to a self-amplifying RNA vaccine

2025 · Wataru Akahata, Mai Komori, et al. · Science Translational Medicine · 24

Epidemiological Correlations Between Head and Neck Cancer and Hepatitis B Core Antibody Positivity

2020 · MAI FUKUSHIMA KOMORI, TAKUJI KIMURA, et al. · Anticancer Research · 22

Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine

2023 · Mai Komori, Amber L. Morey, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 21

Works count: 7

Citation count: 189

H-index: 6

I10-index: 6